Contact
searchSearch
HMP Global
Login

Hepatocellular Carcinoma Excellence Forum

Hepatocellular Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Catherine Wilbur, MD
Videos
Cytokine Biomarkers May Inform First-Line Therapy Selection in Advanced Hepatocellular Carcinoma
03/09/2026
Catherine Wilbur, MD, discusses results from a prospective cytokine analysis of patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors with or without bevacizumab.
Catherine Wilbur, MD, discusses results from a prospective cytokine analysis of patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors with or without bevacizumab.
Catherine Wilbur, MD, discusses...
03/09/2026
Oncology
Richard Finn, MD
Videos
Regorafenib Demonstrates Consistent Benefit in Unresectable Hepatocellular Carcinoma
03/02/2026
Richard S. Finn
Richard Finn, MD, discusses post hoc analysis results from the REFINE study assessing regorafenib in patients with unresectable hepatocellular carcinoma.
Richard Finn, MD, discusses post hoc analysis results from the REFINE study assessing regorafenib in patients with unresectable hepatocellular carcinoma.
Richard Finn, MD, discusses post...
03/02/2026
Oncology
Stephen Lam Chan, MD
Videos
Adjuvant Pembrolizumab Fails to Improve Recurrence-Free Survival in Hepatocellular Carcinoma
01/26/2026
Stephen Lam Chan, MD
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses...
01/26/2026
Oncology
Farshid Dayyani, MD, PhD
Videos
Multimodality Immunotherapy Plus TACE Shows Promise in Liver-Limited Unresectable Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses results from a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular carcinoma, including...
Farshid Dayyani, MD, PhD, discusses results from a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular carcinoma, including...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Farshid Dayyani, MD, PhD
Videos
Multimodality Immunotherapy Plus TACE in Liver-Limited Unresectable Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses the background and methods of a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular...
Farshid Dayyani, MD, PhD, discusses the background and methods of a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Nadine Abi-Jaoudeh, MD
Videos
Transarterial Tirapazamine Embolization Plus Nivolumab Shows Promise in Advanced Hepatocellular Carcinoma
01/13/2026
Nadine Abi-Jaoudeh, MD
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 study evaluating TATE combined with nivolumab in patients with advanced hepatocellular carcinoma who progressed on prior immunotherapy.
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 study evaluating TATE combined with nivolumab in patients with advanced hepatocellular carcinoma who progressed on prior immunotherapy.
Nadine Abi-Jaoudeh, MD,...
01/13/2026
Oncology
Olatunji Alese, MD, Winship Cancer Center
Videos
Dual Immune Checkpoint Blockade for Advanced Hepatocellular Carcinoma
09/17/2025
O. Alese
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses...
09/17/2025
Oncology
Ruth He, MD
Videos
Frontline Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma
04/15/2025
Aiwu Ruth He, MD, PhD
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses...
04/15/2025
Oncology
Ian Tobal, DO, Ochsner Medical Center
Videos
Real World Child-Pugh Scores of Patients With HCC Receiving Immunotherapy
03/27/2025
Ian Tobal, DO, discusses an analysis of real-world Child-Pugh score and outcomes among patients undergoing treatment for hepatocellular carcinoma.
Ian Tobal, DO, discusses an analysis of real-world Child-Pugh score and outcomes among patients undergoing treatment for hepatocellular carcinoma.
Ian Tobal, DO, discusses an...
03/27/2025
Oncology
Laura Dawson, MD, Princess Margaret Cancer Care
Videos
Addition of SBRT to Sorafenib for Patients With Locally Advanced Hepatocellular Carcinoma
03/11/2025
Laura Dawson, MD
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the...
03/11/2025
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use